<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05617794</url>
  </required_header>
  <id_info>
    <org_study_id>CPRO-2207-001</org_study_id>
    <nct_id>NCT05617794</nct_id>
  </id_info>
  <brief_title>Effect of Diffusion Optics Technology (DOT) Spectacle Lenses on Choroidal Thickness</brief_title>
  <acronym>ASH-2</acronym>
  <official_title>Effect of Diffusion Optics Technology (DOT) Spectacle Lenses on Choroidal Thickness and Choroidal Vascularity Index in Emmetropes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SightGlass Vision, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Waterloo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>SightGlass Vision, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to measure the effect of Diffusion Optics Technology (DOT)&#xD;
      spectacle lenses on the choroidal thickness and choroidal vascularity index compared to&#xD;
      control lenses.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 18, 2023</start_date>
  <completion_date type="Anticipated">May 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Choroidal Thickness</measure>
    <time_frame>30 minutes and 60 minutes</time_frame>
    <description>Change from Baseline, 30 minutes and 60 minutes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Retinal and Choroidal Thickness</measure>
    <time_frame>30 minutes and 60 minutes</time_frame>
    <description>Change from Baseline, 30 minutes and 60 minutes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Software Method Comparison</measure>
    <time_frame>30 minutes and 60 minutes</time_frame>
    <description>Comparison of measurements using different software methods; manual, semiautomated and automated software</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Myopia</condition>
  <condition>Myopia Progression</condition>
  <condition>Juvenile Myopia</condition>
  <arm_group>
    <arm_group_label>Treatment 1 - Diffusion Optics Technology (DOT) Pattern</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment 2 - Control Spectacles</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Diffusion Optics Technology (DOT) Pattern Spectacle Lens</intervention_name>
    <description>DOT Pattern Spectacle Lens</description>
    <arm_group_label>Treatment 1 - Diffusion Optics Technology (DOT) Pattern</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Control Spectacle Lens</intervention_name>
    <description>Control Spectacles</description>
    <arm_group_label>Treatment 2 - Control Spectacles</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Are 8-14 years of age;&#xD;
&#xD;
          -  Are able to read (or be read to), understand and sign the assent document;&#xD;
&#xD;
          -  Are accompanied by a parent or legal guardian who is able to read, understand and sign&#xD;
             the parental information and permission document;&#xD;
&#xD;
          -  Are emmetropic by non-cycloplegic auto-refraction, which means both refractive&#xD;
             meridians should be within +1.00D and -1.00D inclusively;&#xD;
&#xD;
          -  Are willing and able to follow instructions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Are participating in any concurrent interventional clinical or research study;&#xD;
&#xD;
          -  Have a history of myopia control treatment in the past year;&#xD;
&#xD;
          -  Have amblyopia in either eye or known to have any other binocular vision disorder,&#xD;
             such as accommodative insufficiency;&#xD;
&#xD;
          -  Have any known active ocular disease and/or infection;&#xD;
&#xD;
          -  Have a systemic condition that in the opinion of the investigator may affect a study&#xD;
             outcome variable. Examples include diabetes mellitus, hyperthyroidism;&#xD;
&#xD;
          -  Are using any systemic or topical medications that in the opinion of the investigator&#xD;
             may affect a study outcome variable. Examples include Atropine eye drops;&#xD;
&#xD;
          -  Have undergone strabismus surgery, refractive error surgery or intraocular surgery;&#xD;
&#xD;
          -  Are a child of a member of the study team.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jill Woods</last_name>
    <phone>1 519-888-4567</phone>
    <email>jwoods@uwaterloo.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Asiya Jabeen</last_name>
    <phone>1 519-888-4567</phone>
    <email>ajabeen@uwaterloo.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre for Ocular Research and Education</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2L 3G1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Asiya Jabeen</last_name>
      <phone>+1 519-888-4567</phone>
      <email>ajabeen@uwaterloo.ca</email>
    </contact>
    <investigator>
      <last_name>Lyndon Jones, PhD, FCOptom</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 1, 2022</study_first_submitted>
  <study_first_submitted_qc>November 11, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2022</study_first_posted>
  <last_update_submitted>April 10, 2023</last_update_submitted>
  <last_update_submitted_qc>April 10, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myopia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

